Latest / This Week In Medicine
NEJM February 2026 A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
This scientific report details a significant medical study on a new treatment for IgA nephropathy, a common and dangerous kidney disease driven by abnormal immune system activity. Researchers tested a drug called atacicept, which works by blocking specific proteins that fuel the production of harmful antibodies responsible for damaging the kidneys. The study found that patients receiving weekly injections experienced a dramatic reduction in protein loss in their urine compared to those who received a placebo, indicating a much healthier kidney function. By effectively slowing the progression…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.